Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Total revenue	$ 48,318,000	$ 37,944,000
Costs and operating expenses:
Research and development	70,923,000	136,457,000
General and administrative	49,043,000	70,287,000
Restructuring charges	5,273,000	0
Total operating expenses	137,286,000	215,946,000
Loss from operations	(88,968,000)	(178,002,000)
Other income (expense):
Interest income, net	6,081,000	11,711,000
Loss on investments	(3,693,000)	(2,544,000)
Change in fair value of warrant liabilities	0	940,000
Other income (expense), net	(4,289,000)	2,015,000
Total other income (expense)	(1,901,000)	12,122,000
Loss before income taxes	(90,869,000)	(165,880,000)
Income tax expense	88,000	31,000
Net loss	$ (90,957,000)	$ (165,911,000)
Net loss per share, basic (in dollars per share)	$ (1.68)	$ (3.31)
Net loss per share, diluted (in dollars per share)	$ (1.68)	$ (3.32)
Weighted average common shares outstanding:
Basic (in shares)	54,241,619	50,111,460
Diluted (in shares)	54,241,619	50,133,366
Comprehensive loss:
Net loss	$ (90,957,000)	$ (165,911,000)
Other comprehensive (loss) income:
Foreign currency translation adjustment	849,000	(3,035,000)
Debt Securities, Available-for-Sale, Unrealized Gain (Loss)	107,000	0
Total other comprehensive (loss) income	956,000	(3,035,000)
Comprehensive loss	(90,001,000)	(168,946,000)
Biosecurity revenue
Total revenue	10,088,000	10,055,000
Biosecurity Segment [Member]
Costs and operating expenses:
Cost of Biosecurity revenue	7,957,000	9,202,000
Product and Service, Other
Costs and operating expenses:
Cost of Biosecurity revenue	4,090,000	0
Cell Engineering Revenue [Member]
Total revenue	$ 38,230,000	$ 27,889,000